Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars

Feb 4 (Reuters) - Eli Lilly forecast 2026 profit above Wall Street estimates on ​Wednesday, betting on surging demand for ‌its obesity drugs as the world's most valuable ‌drugmaker prepares to launch its oral weight-loss pill later this year. Shares of the company rose nearly 7% in premarket trading. Lilly last ⁠year became the ‌first pharmaceutical company to hit a $1 trillion valuation, driven by the ‍popularity of its blockbuster weight-loss drug, Zepbound, and a rapidly expanding obesity market tha ...